SPOC1-Mediated Antiviral Host Cell Response Is Antagonized Early in Human Adenovirus Type 5 Infection

Sabrina Schreiner, Sarah Kinkley, Carolin Bürck, Andreas Mund, Peter Wimmer, Tobias Schubert, Peter Groitl, Hans Will, Thomas Dobner*

Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany

Abstract

Little is known about immediate phases after viral infection and how an incoming viral genome complex counteracts host cell defenses, before the start of viral gene expression. Adenovirus (Ad) serves as an ideal model, since entry and onset of gene expression are rapid and highly efficient, and mechanisms used 24–48 hours post infection to counteract host antiviral and DNA repair factors (e.g. p53, Mre11, Daxx) are well studied. Here, we identify an even earlier host cell target for Ad, the chromatin-associated factor and epigenetic reader, SPOC1, recently found recruited to double strand breaks, and playing a role in DNA damage response. SPOC1 co-localized with viral replication centers in the host cell nucleus, interacted with Ad DNA, and repressed viral gene expression at the transcriptional level. We discovered that this SPOC1-mediated restriction imposed upon Ad growth is relieved by its functional association with the Ad major core protein pVII that enters with the viral genome, followed by E1B-55K/E4orf6-dependent proteasomal degradation of SPOC1. Mimicking removal of SPOC1 in the cell, knockdown of this cellular restriction factor using RNAi techniques resulted in significantly increased Ad replication, including enhanced viral gene expression. However, depletion of SPOC1 also reduced the efficiency of E1B-55K transcriptional repression of cellular promoters, with possible implications for viral transformation. Intriguingly, not exclusive to Ad infection, other human pathogenic viruses (HSV-1, HSV-2, HIV-1, and HCV) also depleted SPOC1 in infected cells. Our findings provide a general model for how pathogenic human viruses antagonize intrinsic SPOC1-mediated antiviral responses in their host cells. A better understanding of viral entry and early restrictive functions in host cells should provide new perspectives for developing antiviral agents and therapies. Conversely, for Ad vectors used in gene therapy, counteracting mechanisms eradicating incoming viral DNA would increase Ad vector efficacy and safety for the patient.

Citation: Schreiner S, Kinkley S, Bürck C, Mund A, Wimmer P, et al. (2013) SPOC1-Mediated Antiviral Host Cell Response Is Antagonized Early in Human Adenovirus Type 5 Infection. PLoS Pathog 9(11): e1003775. doi:10.1371/journal.ppat.1003775

Editor: Michael J. Imperiale, University of Michigan, United States of America

Received July 12, 2013; Accepted October 4, 2013; Published November 21, 2013

Copyright: © 2013 Schreiner et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The Heinrich Pette Institute, Leibniz Institute for Experimental Virology is supported by the Freie und Hansestadt Hamburg and the Bundesministerium für Gesundheit (BMG). SS is supported by grants from the Peter und Traudl Engelhorn-Stiftung, the Erich und Gertrud Roggenbuck-Stiftung and the B. Braun-Stiftung. TD is supported by the Wilhelm Sander-Stiftung and the Deutsche Forschungsgemeinschaft. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: thomas.dobner@hpi.uni-hamburg.de

Introduction

DNA viruses require nuclear transport of their genomes to productively infect the host cell and initiate efficient replication. Simultaneously, introduction of viral nucleic acids into the host cell nucleus triggers danger signals, and activates DDR (DNA damage response) prior to cell cycle arrest, and apoptosis. Many viruses counteract these regulatory measures in infected cells in order to ensure productive infection, which necessitates proper viral gene expression and adequate progeny synthesis [1].

In line with this, Ad (Adenoviruses) have gained functions to modulate DSBR (double-strand break repair), apoptosis, cellular gene expression, and host cell immune responses. The incoming viral genome is complexed with core factors and capsid protein VI after endosomal release. Our recent work showed that Ad DNA remains transcriptionally inactive until protein VI mediates activation of the viral E1A promoter by functionally inhibiting chromatin-associated transcription factor Daxx [2]. Ad E1A (early region 1A protein) is the first protein expressed after infection, playing an essential role in subsequent transcriptional activation, and induction of cell cycle progression [3].

Recently, E1A was seen to interact with the cellular PML-II isoform, and together this complex elevates transcription from Ad promoters [4]. E1B-55K (early region 1B 55 kDa protein) supports efficient viral replication by inhibiting anti-proliferative processes induced by the host cell [5]. However, additional functions of E1B-55K mainly require its interaction with E4orf6 (early region 4 open reading frame protein 6). So far, several reports have demonstrated that Ad E4orf6 connects Ad E1B-55K to an E3 ubiquitin ligase complex in the nucleus, containing cellular factors Rbx1/Roc1/Hrt1, Elongin B/C, and either Cullin 2 or Cullin 5 [6]. Recent work has shown that E1B-55K is the substrate recognition unit, while E4orf6 assembles the cellular components, and this functional complex sequesters cellular target proteins into a proteasomal degradation pathway C [6,7,8,9,10,11,12,13]. Another hurdle to the viability and propagation of DNA viruses is imposed by host DDR and repair machinery. To counter this, several DNA viruses have acquired early viral genes that degrade
or redistribute key cellular factors of the repair machinery to protect viral genome integrity [6]. Ad-mediated DDR inhibition by the Ad E1B-55K/E4orf6 E3 ubiquitin ligase complex and E4orf3 (early region 4 open reading frame 3)-dependent relocalization of the MRN complex into nuclear tracks and cytoplasmic inclusions together block concatenated formation and DNA damage signaling, therefore allowing productive infection and efficient virus growth [14,15,16,17,18].

The human SPOC1 (survival-time associated PHD protein in ovarian cancer 1/PHF13) protein has been identified as a novel regulator of DDR and chromatin structure [19,20]. The spoc1 gene is located in chromosomal region 1p36.23, a region with frequent heterozygous deletions implicated in tumor development and progression [21,22]. Consistent with this, elevated SPOC1 RNA levels in primary and recurrent epithelial ovarian cancers have been associated with decreased survival rates in patients [23]. Moreover, SPOC1 RNA can be detected in most human tissues, with the highest levels in the testis, where it has been exclusively detected in spermatogonia [23,24].

SPOC1 is a nuclear protein with a PHD (plant homeodomain), predicted to bind H3K4me2/3 and to regulate chromatin-specific interactions [20,25]. In line with this, Kinkley and co-workers observed that SPOC1 is dynamically associated with chromatin and induces chromosome condensation to regulate proper cell division [20]. Particularly, SPOC1 plays a role in radioresistance and DNA repair by selective modulation of, and functional cooperation with chromatin modifiers and DDR regulators [19].

There is also evidence that SPOC1 is recruited to DSBs and regulates the kinetics of DSB repair and cellular radioresistance. It is proposed that H3K4me2/3-containing chromatin can be converted into more compact chromatin by SPOC1-mediated increase of H3K9 KMTs and H3K9me3. Hence, loss of SPOC1 promotes chromatin decondensation, and is associated with increased levels of DDR transducers and efficient DNA repair. The correlation between SPOC1 protein levels and H3K9me3, as well as expression of several H3K9 KMTs, implicates SPOC1 functions in both chromatin condensation and DDR [19]. In sum, SPOC1 is a multifunctional protein with a additional role in stem cell differentiation, oncogenesis, chromatin structure, and DNA repair processes.

Here, we identified SPOC1 as a novel host restriction factor targeted during viral infection. SPOC1 protein levels decreased in Ad infected cells, which we could attribute to proteasomal degradation mediated by the E1B-55K/E4orf6 E3 ligase complex. Not only did SPOC1 interact with E1B-55K, but also Ad5 E2A-DBP, a marker for nuclear Ad replication sites, as seen by co-immunoprecipitation and immunofluorescence assays. When SPOC1 was overexpressed, Ad virus yield, viral DNA synthesis, and viral protein synthesis decreased; reporter gene and chromatin immunoprecipitation assays showed that SPOC1 repressed gene expression at the level of transcription. Intriguingly, interaction with structural viral core protein pVII initially stabilized SPOC1 protein levels before expression of any viral early proteins.

Results

Ad5 E3 ubiquitin ligase complex targets SPOC1 for proteasomal degradation

SPOC1 induces chromosome condensation [20], stimulates cellular gene silencing and influences DDR, which potentially contributes to its transformation potential [19]. Since host DDR prevents viability and propagation of DNA viruses, Ad efficiently targets a multitude of host cell DSB repair regulatory factors in order to promote productive infection [9,10,17,26,27]. Based on these data, we examined SPOC1 protein levels in infected human cells, and observed SPOC1 levels reproducibly reduced after 24 hours post infection (Fig. 1A). This decrease was even more pronounced at a higher multiplicity of infection (data not shown), and was comparable to the reduction of already known targets of the E1B-55K/E4orf6 E3-ubiquitin ligase complex [6].

To discover whether SPOC1 is a new host cell substrate of the Ad5 E3 ubiquitin ligase complex, we determined SPOC1 protein concentrations in wild type (H5pm4100), and mutant-virus infected cells lacking either E1B-55K (H5pm4149) or E4orf6 (H5pm4154) (Fig. 1B). As anticipated, SPOC1 was dramatically reduced in cells infected with the wild type virus H5pm4100 (Fig. 1B, lane 2), whereas the cellular protein accumulated to levels comparable to non-treated cells lacking E1B-55K (H5pm4149; Fig. 1B, lane 3). Similarly, SPOC1 was not reduced in cells infected with the E4orf6-minus virus mutant H5pm4145 (Fig. 1B, lane 4). We further examined SPOC1 protein levels in H1299 cells infected with an E4orf6 virus mutant (H5pm4139) carrying point mutations in the BC Box that abrogate the formation of the Ad5 E3 ubiquitin ligase complex, by inhibition of E4orf6 binding to Elongins B and C. Again activity of the E1B-55K/E4orf6 E3 ligase complex apparently played a role in reducing SPOC1 protein concentrations (Fig. 1B, lane 5). Consistent with previous publications, Mre11 was not degraded during lytic infection with the BC Box virus mutant H5pm4139 (Fig. 1B, lane 5). Our results confirm that the formation and ligase activity of the E1B-55K/E4orf6 ubiquitin complex are essential to reduce SPOC1 protein levels.

To confirm that we had identified SPOC1 as a novel target of viruses-induced proteasomal degradation via E1B-55K/E4orf6-dependent E3 ligases, we treated infected cells with the proteasome inhibitor MG-132 (Fig. 2A). Functionally inhibiting host cell proteasomes abolished Mre11 and SPOC1 reduction seen in wild type infected cells, supporting the role of ubiquitin proteasome system in SPOC1 degradation.
Figure 1. SPOC1 is reduced during Ad infection. H1299 cells were infected with wild type H5pg4100 at a multiplicity of 50 FFU per cell. Cells were harvested after indicated time points post infection, total-cell extracts were prepared, separated by SDS-PAGE and subjected to immunoblotting. (A) Immunoblotting using mouse monoclonal antibody M73 (E1A), 2A6 (E1B-55K), RSA3 (E4orf6), rat monoclonal SPOC1 antibody and mouse monoclonal antibody AC-15 (β-actin) as a loading control. (B) H1299 cells were infected with wildtype (H5pg4100) and mutant viruses (H5pm4149, H5pm4154, H5pm4139) at moi of 50 FFU per cell. Cells were harvested after 48 hours, and immunoblotted using the antibodies above, plus rabbit polyclonal Mre11 antibody. doi:10.1371/journal.ppat.1003775.g001

Figure 2. Proteasomal degradation of SPOC1 by the E1B-55K/E4orf6 E3 ubiquitin ligase complex. (A) H1299 cells were infected with wildtype (H5pg4100) and mutant viruses (H5pm4149, H5pm4154) at moi of 50 FFU per cell. Cells were treated for six hours with proteasome inhibitor (+MG 132), before total-cell extracts were prepared 48 h p.i.. Proteins were separated by SDS-PAGE and subjected to immunoblotting using mouse monoclonal antibody 2A6 (E1B-55K), RSA3 (E4orf6), rat monoclonal SPOC1 antibody and mouse monoclonal antibody AC-15 (β-actin) as a loading control. (B) H1299 cells were transfected with pcDNA3-derived plasmids expressing wildtype E1B-55K, E4orf6, or a combination of both. Cells were harvested 48 hours post infection. Total cell extracts were prepared and specific proteins were immunoblotted as described in A. doi:10.1371/journal.ppat.1003775.g002
We finally validated our findings by analyzing the levels of SPOC1 protein in transfected cells (Fig. 2B). Expression of E1B-55K alone (Fig. 2B, lane 2) or E4orf6 alone (Fig. 2B, lane 3) had no effect on steady-state concentrations of endogenous SPOC1 protein, while expression of both E1B-55K and E4orf6 (Fig. 2B, lane 4) diminished SPOC1 steady-state concentrations to levels similar to virus-infected cells (Fig. 1 and 2A).

**Ad5 E1B-55K binds and induces cytoplasmic relocation of SPOC1**

Since E1B-55K is the substrate recognition unit of the SCF-like E3 ubiquitin ligase, we next tested whether E1B-55K interacts with the endogenous SPOC1 protein. As anticipated, in E1B-55K-transfected human H1299 cells E1B-55K co-immunoprecipitated with SPOC1-specific antibody, revealing an interaction between these factors (Fig. 3A, lane 2). No E1B-55K signal was observed in the corresponding negative controls (Fig. 3A, lane 1).

The next question was whether E1B-55K interferes with the intracellular localization of SPOC1. Consistent with previous findings, immunofluorescence analysis in E1B-transfected human cells revealed that wild type E1B-55K protein localizes in the cytoplasm, mostly concentrated in perinuclear bodies (Fig. 3B, panel F, H; [28,29,30,31,32,33,34]). In contrast to the diffuse nuclear localization in non-treated cells (Fig. 3B, panel C, D), SPOC1 was completely sequestered into the E1B-containing aggregates in the presence of the viral protein (Fig. 3B, panel G, H).

**SPOC1 is recruited into Ad replication centers**

To gain better understanding of SPOC1 role during Ad infection, we investigated the subcellular localization of SPOC1 in infected human DLD1 cells, which stably overexpress SPOC1 after doxycyclin treatment to overcome degradation of the cellular factor (Fig. S1). In mock-infected cells, SPOC1 is diffusely distributed inside the nucleus in approximately 90% of the cells investigated (n = 50; data not shown). When monitored together with Ad5 E2A-DBP, a marker for Ad replication sites in the nucleus, at 24 to 48 hours post infection SPOC1 colocalized with...
Figure 4. SPOC1 is recruited to Ad replication centers during infection. (A) Human DLD1 cells, which stably overexpress SPOC1 after doxycyclin treatment to overcome degradation of the cellular factor, were infected with wildtype H5pg4100 at a moi of 10 FFU per cell; throughout the experiment the cells were grown in media supplied with doxycyclin. After indicated time points, cells were fixed with methanol and labeled with E2A/DBP mouse mab B6-8 and SPOC1-specific rat monoclonal antibody. Primary antibodies were detected with Texas Red or FITC conjugated secondary antibody. Representative staining patterns are shown. Nuclei are visualized by DAPI staining (magnification ×7600). Additionally, merge panels show colocalization of the indicated proteins. (B) DLD1 (left panel) and U2OS (right panel) cells, which stably overexpress SPOC1 after doxycyclin treatment were infected with wildtype (H5pg4100) and mutant viruses (H5pm4149, H5pm4154) at moi of 50 FFU per cell. Cells were treated with doxycyclin 12 hours before infection and throughout the experiment to stably induce SPOC1 expression, before total cell extracts were prepared 24 hours post infection. E1B-55K and E2A/DBP were immunoprecipitated using rabbit polyclonal SPOC1 antibody. Proteins were separated on 10% SDS-PAGE and visualized by immunoblotting. Input levels of total-cell lysates and co-precipitated proteins were detected using monoclonal antibody 2A6 (E1B-55K), B6-8 (E2A/DBP), SPOC1-specific rat monoclonal antibody, and mouse monoclonal antibody AC-15 (β-actin) as a loading control.

doi:10.1371/journal.ppat.1003775.g004

sites of viral replication in approximately 60% of cells (n = 50; Fig. 4A, panels D, H, L and P). We confirmed our observation by monitoring SPOC1/E2A-DBP association using immunoprecipitation analysis after wild type and mutant virus infection in DLD1 and U2OS cells stably overexpressing SPOC1 after doxycyclin treatment (Fig. 4B). As expected, E2A-DBP co-immunoprecipitated with SPOC1-specific antibody, revealing an interaction in all infected SPOC1-overexpressing human cells (Fig. 4B, lanes 2, 3, 4, 6, 7, 8), whereas no signal was obtained in the corresponding negative controls (Fig. 4B, lanes 1 and 5). We also were able to confirm the SPOC1/E1B-55K interaction within the infected SPOC1-induced cells. To further test specificity of the SPOC1 antibody used in all of the colPs, we tested SPOC1 binding after protosomal degradation of SPOC1 (Fig. S1). Therefore, we infected H1299 cells with Ad5 wild type virus (H5pg1100) and virus mutants depleted for either E1B-55K (H5pm4149) or E4orf6 (H5pm4154) expression. After 24 and 48 hours post infection, total cell extracts were prepared. E1B-55K and E2A/DBP were immunoprecipitated using rabbit polyclonal SPOC1 antibody. Proteins were separated on 10% SDS-PAGE and visualized by immunoblotting. Input levels of total-cell lysates and co-precipitated proteins were detected using monoclonal antibody 2A6 (E1B-55K), B6-8 (E2A/DBP), SPOC1-specific rat monoclonal antibody, and mouse monoclonal antibody AC-15 (β-actin) as a loading control. As expected, E2A-DBP co-immunoprecipitated with SPOC1-specific antibody (Fig. S2, lanes 3, 5–8), only revealing binding in infected cells, whereas SPOC1 could not be degraded due to the time point (Fig. S2, lane 3) or the absence of either E1B-55K (Fig. S2, lanes 5 and 6) or E4orf6 (Fig. S2, lanes 7 and 8). We also were able to confirm the specific SPOC1/E1B-55K interaction within the infected cells expressing SPOC1 and E1B-55K (Fig. S2, lanes 3, 7 and 8). Together these data improved our co-immunoprecipitation analysis and reassured specificity of the SPOC1 antibody used in these experiments. Together, our results show that the cellular factor SPOC1 associates with E2A-DBP within Ad5 replication compartments in virus-infected human cells. This novel observation prompted us to investigate whether SPOC1 is linked to Ad transcriptional regulation during productive infection. Such recruitment to nuclear sites associated with viral genome replication suggests that SPOC1 is involved in regulating Ad5 gene expression.

SPOC1 overexpression reduces Ad gene expression

To better analyze the role of SPOC1 during Ad5 infection, we performed experiments in SPOC1-inducible human colon carcinoma (DLD1) and osteosarcoma (U2OS) cell lines, which express exogenous SPOC1 after doxycyclin (dox) treatment. Prior to our analysis, we investigated SPOC1 protein expression in the absence and presence of dox (Fig. 3A). Additionally, proliferation of the SPOC1 overexpressing cells was quantified, revealing no significant difference in comparison to the uninduced controls (Fig. S1).

To assess the effect of SPOC1 on overall virus growth, we determined total virus yield after SPOC1 induction in DLD1 cells (Fig. 5B). SPOC1 overexpression reduced progeny production seven- (48 h p.i.) to eight-fold (72 h p.i.) compared to non-treated DLD1 control cells (Fig. 5B). When we analyzed Ad5 progeny production in SPOC1 inducible U2OS cells we observed similar effects (Fig. 5B).

These results suggest that SPOC1 mediates repressive effects during Ad5 infectious cycle. To further validate this hypothesis, expression of viral early and late proteins was monitored at different time points after infection (Fig. 5C). Consistent with Ad5 progeny production, protein synthesis was inefficient in SPOC1 overexpressing DLD1 and U2OS cells (Fig. 5C). Particularly expression of E1A was affected, since it was substantially higher in non-treated DLD1 (Fig. 5C, upper panel lanes 1–6) and U2OS (Fig. 5C, lower panel lanes 1–6). Similar effects were observed when monitoring viral DNA synthesis in infected cells. As with Ad5 progeny production (Fig. 5D), DNA synthesis was less efficient in SPOC1 induced cells than in uninduced cells (Fig. 5D). Next we investigated whether Ad transcription is negatively regulated by SPOC1 expression. Therefore, we analyzed whether early and late viral mRNA levels are affected by SPOC1 overexpression in Ad wild type virus infected cells. We observed that viral early E1A and E1B mRNA production is lower in SPOC1 induced cells, compared to cells lacking treatment with doxycyclin (Fig. 5E). Similar results were obtained for hexon mRNA expression, suggesting either an impact of enhanced synthesis of early gene products or direct repression of the late promoter (Fig. 5E). Moreover, we tested cellular mRNA levels to exclude non-specific repression of gene expression by SPOC1 expression affecting cellular RNA Pol II transcription (Fig. 5E). Our results show similar GAPDH mRNA synthesis in the cells tested, indicating that SPOC1 expression does not reflect an overall reduction in cellular RNA pol II transcription.

To validate these observations and to exclude non-specific impact of the overexpression studies, we depleted SPOC1 expression by transient knock-down with siRNA (Fig. 6A) and analyzed Ad5 replication. Virus growth was enhanced three-fold (24 h p.i.) to five-fold (48 h p.i.) in the absence of SPOC1, compared to control cells (Fig. 6B). Consistent with data observed in DLD1 and U2OS cells, early and late viral protein synthesis was more efficient in SPOC1-depleted cells (Fig. 6C). DNA synthesis was monitored and showed two-fold more efficient synthesis of viral DNA in SPOC1-depleted cells compared to the control cells (Fig. 6D). To further investigate a role of SPOC1 in Ad transcription and viral mRNA synthesis, we analyzed whether early and late viral mRNA levels are affected by the absence of SPOC1 expression in infected cells (Fig. 6E). We observed that viral early E1A and E1B mRNA production is two-fold reduced in

Ad5-Mediated Inhibition of SPOC1

PLOS Pathogens | www.plospathogens.org 6 November 2013 | Volume 9 | Issue 11 | e1003775

significant difference in comparison to the uninduced controls (Fig. S1).

To assess the effect of SPOC1 on overall virus growth, we determined total virus yield after SPOC1 induction in DLD1 cells (Fig. 5B). SPOC1 overexpression reduced progeny production seven- (48 h p.i.) to eight-fold (72 h p.i.) compared to non-treated DLD1 control cells (Fig. 5B). When we analyzed Ad5 progeny production in SPOC1 inducible U2OS cells we observed similar effects (Fig. 5B).

These results suggest that SPOC1 mediates repressive effects during Ad5 infectious cycle. To further validate this hypothesis, expression of viral early and late proteins was monitored at different time points after infection (Fig. 5C). Consistent with Ad5 progeny production, protein synthesis was inefficient in SPOC1 overexpressing DLD1 and U2OS cells (Fig. 5C). Particularly expression of E1A was affected, since it was substantially higher in non-treated DLD1 (Fig. 5C, upper panel lanes 1–6) and U2OS (Fig. 5C, lower panel lanes 1–6). Similar effects were observed when monitoring viral DNA synthesis in infected cells. As with Ad5 progeny production (Fig. 5D), DNA synthesis was less efficient in SPOC1 induced cells than in uninduced cells (Fig. 5D). Next we investigated whether Ad transcription is negatively regulated by SPOC1 expression. Therefore, we analyzed whether early and late viral mRNA levels are affected by SPOC1 overexpression in Ad wild type virus infected cells. We observed that viral early E1A and E1B mRNA production is lower in SPOC1-induced cells, compared to cells lacking treatment with doxycyclin (Fig. 5E). Similar results were obtained for hexon mRNA expression, suggesting either an impact of enhanced synthesis of early gene products or direct repression of the late promoter (Fig. 5E). Moreover, we tested cellular mRNA levels to exclude non-specific repression of gene expression by SPOC1 expression affecting cellular RNA Pol II transcription (Fig. 5E). Our results show similar GAPDH mRNA synthesis in the cells tested, indicating that SPOC1 expression does not reflect an overall reduction in cellular RNA pol II transcription.

To validate these observations and to exclude non-specific impact of the overexpression studies, we depleted SPOC1 expression by transient knock-down with siRNA (Fig. 6A) and analyzed Ad5 replication. Virus growth was enhanced three-fold (24 h p.i.) to five-fold (48 h p.i.) in the absence of SPOC1, compared to control cells (Fig. 6B). Consistent with data observed in DLD1 and U2OS cells, early and late viral protein synthesis was more efficient in SPOC1-depleted cells (Fig. 6C). DNA synthesis was monitored and showed two-fold more efficient synthesis of viral DNA in SPOC1-depleted cells compared to the control cells (Fig. 6D). To further investigate a role of SPOC1 in Ad transcription and viral mRNA synthesis, we analyzed whether early and late viral mRNA levels are affected by the absence of SPOC1 expression in infected cells (Fig. 6E). We observed that viral early E1A and E1B mRNA production is two-fold reduced in
Figure 5. SPOC1 overexpression represses Ad5 gene expression. (A) To validate the model system, DLD1 or U2OS cells were treated with doxycyclin 12 hours before infection to induce SPOC1 expression; throughout the experiment the cells were grown in media supplied with doxycyclin. Cell extracts were subjected to 10% PAGE and immunoblotting using rat monclonal SPOC1 antibody and mouse monoclonal antibody AC-15 (β-actin) as a loading control. (B) DLD1/U2OS cells were infected with wild type H5pg4100 at a multiplicity of 50 FFU per cell. Viral particles were harvested at the indicated time-points after infection and virus yield was determined by quantitative E2A-72K immunofluorescence staining on HEK293 cells. The results represent the average from three independent experiments and were normalized to values for particle synthesis in SPOC1 induced cells infected with wild type H5pg4100. (C) DLD1/U2OS cells were infected with wild type H5pg4100 at a multiplicity of 50 FFU per cell. Total cell extracts were prepared at the indicated times post infection. Proteins were separated by 10% SDS-PAGE, and immunoblotted with mouse monoclonal antibody M73 (E1A), 2A6 (E1B-55K), anti-Ad5 rabbit polyclonal serum L133, rat monclonal SPOC1 antibody and mouse monoclonal antibody AC-15 (β-actin) as a loading control. (D) DLD1/U2OS cells were infected with wild type H5pg4100 at a multiplicity of 50 FFU per cell. Total cell extracts were prepared and treated with proteinase K. PCR was performed using E1B-specific primers (E1B-fw 3′-CGC GGG ATC CAT GGA GCG AAG AAA CCC ATC TGA GC-5′; E1B-rev 3′-CGG TGT CTG GTC ATT AAG CTA AAA-5′). The Gene Snap Software (Syngene). The results shown represent the averages from three independent experiments. (E) DLD1/U2OS cells were infected with wild type H5pg4100 at a multiplicity of 50 FFU per cell. 24 h p.i. total RNA was
SPOC1 expressing cells, compared to cells lacking this cellular transcription factor. Results obtained for hexon mRNA expression showed three-fold difference in viral mRNA expression (Fig. 6E). As shown above, we did not observe altered GAPDH mRNA levels, indicating that SPOC1 depletion does not affect cellular transcription in general (Fig. 6E).

To exclude that SPOC1 expression impacts on virus entry, we analyzed whether capsid protein VI from incoming Ad capsids show altered accumulation in the host cell nuclear fraction. Using nucleo-cytoplasmic fractionation, we observed rapid protein VI accumulation in the nuclear fraction after infection of U2OS control cells and cells treated with doxycyclin to induce SPOC1 accumulation in the nuclear fraction after infection of U2OS cells. In the absence of other viral factors, SPOC1 was able to repress luciferase expression from all the viral promoters tested (Fig. 7A).

To exclude non-specific repression of gene expression, we investigated whether we can detect SPOC1-dependent effects on the cellular E2F-dependent H2A promoter (Fig. S4). In contrast to the viral reporter constructs, co-expression of SPOC1 did not affect transcription from the cellular promoter (Fig. S4, lanes 3 and 4). The inhibitory effect of SPOC1 expression is specific at least for the promoter sequences tested so far.

To further demonstrate direct association of SPOC1 with Ad promoter sequences, we performed chromatin immunoprecipitation assays from wild type virus infected cells, using SPOC1-specific monoclonal antibody, unrelated IgG control antibody and Ad promoter-specific oligonucleotides (Fig. 7B). The results show that SPOC1 is associated with E1A, E1B, E2early and MLP Ad promoters in infected cells (Fig. 7B). Conclusively, these results indicate that SPOC1 is a component of host cell antiviral mechanisms, playing an important role in the Ad gene expression program through transcriptional repression of viral promoters.

Functional cooperation between SPOC1 and Ad core protein VII

SPOC1 has been previously reported to bind histone H3 and to be capable of promoting repressive epigenetic transitions. Since Ad major core protein VII shares homology with the N-terminal regulatory tail of histone H3 [33], we investigated if SPOC1 may also associate pVII. Whole extracts from H1299 cells that had been transfected with plasmid DNA expressing pVII products (Fig. 8A, lanes 1–3) as well as Ad wild type infected lysates (Fig. 8A, lanes 4 and 5) were immunoprecipitated with SPOC1 specific ab and analyzed by Western blotting using anti-HA mab (Fig. 8A). We detected co-immunoprecipitation of SPOC1 with pVII, when both factors were present (Fig. 8A, lanes 2, 3 and 5). As core protein pVII remains associated with the viral genome during entry [36], we performed further pVII transfection studies mimicking immediate early phase of infection (Fig. 8B). First, we observed a significant increase in SPOC1 protein levels (Fig. 8B, lane 2) and repressive H3K9me3 histone marks as expected due to other reports [19]; Fig. 8B, lane 2. We carried out additional infection studies with H5pg1401 Ad wild type virus infected cells (Fig. 8C). Again, we monitored SPOC1 and H3K9me3 protein levels and detected loss of H3K9me3, most presumably due to SPOC1 reduction by proteasomal degradation via E1B-55K/E4orf6 E3 ubiquitin ligases (Fig. 8C, lane 2). As pVII was reported to occupy Ad DNA during the immediate early phase of infection [36,37,38,39], we expect results indicate that during early Ad infection, pVII likely protects its genome from SPOC1 mediated repression silencing, prior to the onset of transcription by pVII removal from the genome [40,41] indicating loss of pVII-bound repressive factor SPOC1.

Downregulation of antiviral host factor SPOC1 is not restricted to Ad5 lytic infection

To determine whether SPOC1 is a key player in antiviral defense in general, and whether strategies to restrain SPOC1 are conserved among different human pathogenic viruses, we tested protein expression in permissive cell lines infected with HSV-1 (herpes simplex virus type 1; Fig. 9A), HSV-2 (herpes simplex virus type 2; Fig. 9A), HIV-1 (human immunodeficiency virus type 1; Fig. 9B) or HCV (human hepatitis C virus; Fig. 9C). To evaluate efficient infection, we monitored viral protein levels of HSV-1 nucleocapsid protein crossreacting with HSV-2 nuclear protein (Fig. 9A), HIV-1 p24 (Fig. 9B) or HCV NS5A (Fig. 9C). Intriguingly, we detected significantly reduced SPOC1 protein levels in all virus-infected cells (Fig. 9). Taken together, functional inhibition of the antiviral host factor SPOC1 by Ad early proteins E1B-55K and E4orf6 can also be achieved by other viral factors expressed in the course of HSV-1, HSV-2, HIV-1 and HCV infection.

Discussion

Viruses exploit cellular pathways for their own benefit, often achieved by providing high affinity binding sites on viral factors that recruit key regulatory proteins from cellular pathways to outcompete their physiological binding partner. This strategy allows viruses to infect cells and establish efficient replication with nothing more than the incoming viral genome and viral capsids. Besides transport of the genome to appropriate replication sites, viruses also need to assure decondensation and transcriptional activation of the viral genome, which in most cases has been packed and stored in the most economical way. Once the viral genome becomes transcriptionally activated new viral proteins are synthesized providing the virus with the capacity to reprogram the cell for viral replication. All of the very early steps during viral infection represent an essential moment in establishing productive infection of all human pathogenic viruses, but are as yet poorly characterized. In this report, we show that the cellular protein SPOC1 is tightly regulated in the course of productive Ad infection, identifying SPOC1 as a viral restriction factor in cellular defense. Ad
Figure 6. SPOC1 depletion enhances Ad5 gene expression. (A) H1299 cells were transfected with siRNA constructs against SPOC1 (si768, 5'-UCA CCU GUC CUG UGC GAA AdTdT-3') and control siRNA (5'-AGG UAG UGU AAU CGC CUU GdTdT-3'). Cells were harvested at 24 and 48 hours post transfection. Total cell extracts were prepared and proteins were separated by SDS-PAGE and subjected to immunoblotting using SPOC1-specific rat monoclonal ab. β-actin was included as a loading control. (B) H1299 cells were treated with indicated siRNAs to induce SPOC1 depletion and infected 24 hours post transfection with wild type H5pg4100 at a multiplicity of 50 FFU per cell. Viral particles were harvested at the indicated time-points after infection and virus yield was determined by quantitative E2A-72K immunofluorescence staining on HEK293 cells. The results represent the average from three independent experiments. (C) H1299 cells were infected with wild type H5pg4100 at a multiplicity of 50 FFU per cell. Total-cell extracts were prepared at the indicated times post infection. Proteins were separated by 10% SDS-PAGE, and immunoblotted with mouse monoclonal antibody M73 (E1A), 2A6 (E1B-55K), anti-Ad5 rabbit polyclonal serum L133, rat monoclonal SPOC1 antibody and mouse monoclonal antibody AC-15 (β-actin) as a loading control. (D) H1299 cells were infected with wild type H5pg4100 at a multiplicity of 50 FFU per cell. Total cell extracts were prepared and treated with proteinase K. PCR was performed using E1B-specific primers (E1B-fw 3'-CGC GGG ATC CAT GGA GCG AAG AAA CCC ATC TGA GC-5'; E1B-rev 3'-CGG TGT CTG GTC ATT AAG CTA AAA-5'). The same amounts of PCR product were separated on an analytic agarose gels (1%) and quantification was achieved with the Gene Snap Software (Syngene). The results shown represent the averages from three independent experiments. (E) H1299 cells were infected with wild type H5pg4100 at a multiplicity of 50 FFU per cell. 24 h p.i. total RNA was extracted,
possesses strategies to neutralize SPOC1 via an E1B-55K/E4orf6-dependent proteasomal degradation pathway. Moreover, functional inhibition of SPOC1 seems to be conserved among different human pathogenic viruses.

Despite the well-characterized functions of Ad early genes and core/capsid proteins, it is still unclear how Ad transcription is initiated in detail. To summarise our findings we have put together a scheme of how various factors may interact at early stages after Ad infection (Fig. 10). Initially, the genome enters the cell as a highly condensed, transcriptionally inactive nucleoprotein complex, assembled with capsid and core proteins pVI and pVII, identified to recruit cellular factors to the Ad genome Fig. 10; [20,25]. Recently, we reported transactivating properties of protein VI involving a conserved PPSI motif for binding to ubiquitin ligases of the Nedd4 family of E3 ubiquitin ligases, prior to Ad-dependent depletion of Daxx/ATRX dependent transcriptional restriction Fig. 10; [2].

The Ad major core protein VII remains bound to the Ad genome during the early phase of infection and is subsequently released due to transcription Fig. 10; [37]; however the duration and amount of pVII complexed with the viral genome is still unclear. Moreover, it also remains elusive whether complete disassociation of pVII from viral DNA is required for active transcription. Nevertheless, pVII is the most abundant structural component of the viral core, is strongly associated with viral DNA in a sequence-independent manner [43], and shares homology with the N-terminal regulatory tail of histone H3 [35]. When this viral factor is imported into the nucleus together with the viral genome, it apparently packages the incoming viral DNA into chromatin-like structures Fig. 10; [37,44,45,46,47].

SPOC1 is a nuclear PHD-protein, predicted to bind H3K4me2/3 and to regulate chromatin-specific interactions [20,25]. Therefore, SPOC1 is dynamically associated with chromatin, and plays a major role in chromosome condensation to regulate proper cell division [20]. It is proposed that H3K4me2/3-containing chromatin is converted into more compact chromatin by SPOC1-mediated increase of H3K9 KMTs (lysine methyltransferases) and H3K9me3 [19].

We observed an association between SPOC1 and viral promoter regions; and with Ad core protein pVII in the absence of any other viral protein, and during Ad infection (Fig. 7B; Fig. 8; Fig. 10). We also observe SPOC1-mediated pVII stabilization, 48 hours post transfection (Fig. 8) and hypothesize that pVII cooperation with viral DNA protects the incoming viral genome from immediate early checkpoint signaling. In accordance with recent observations by Karen and co-workers, we believe that pVII prevents the onset of DNA repair signals prior to efficient viral gene expression [36].

These ideas are further supported by recent evidence that SPOC1 expression levels have a strong impact on DDR, DNA repair, and cellular radiosensitivity [19]. It was observed that SPOC1 and associated factors are recruited to DSBs to modulate chromatin structure as well as DDR. Due to SPOC1 binding and stabilization of repressive factors, i.e. H3K9 KMTs and H3K9me3, this antiviral protein helps conversion into a compact chromatin status (Fig. 10). Conversely, loss of SPOC1 releases several factors and repressive histone marks, promoting chromatin decondensation.

In the early phase of Ad productive infection SPOC1 is recruited to the viral genome and Ad5 replication centers (Fig. 4; Fig. 7B). The SPOC1-rich chromatin environment promotes the activation and recruitment kinetics of DDR transducers (γH2AX, pATM) [19]. However, the Ad core protein pVII masks the genome and antagonizes recognition by host cell repair factors (Fig. 10). Subsequently, core protein VII and pVII bound SPOC1 is released from viral DNA prior to synthesis of Ad replication proteins E2A-DBP, resulting in recognition of viral origins of DNA replication. The replication proteins presumably compete with components of DDR for binding to Ad sequences to form a functional preinitiation complex prior to DDR being inhibited by E1B-55K, E4orf6 and E4orf3.

Interestingly, the correlation between SPOC1 protein levels and H3K9me3 implies that Ad may regulate expression of several H3K9 KMTs. H3K9me3 is not only an epigenetic marker characteristic of heterochromatin, but is also the direct binding platform of cellular and/or viral factors that regulate heterochromatin compaction and spreading [48,49]. In line with this, Gupta and coworkers recently showed that Ad-dependent E1B-55K/E4orf6 E3 ubiquitin ligase induces proteasomal degradation of the acetyltransferase TIP60 [10]. TIP60 chromodomain binding to H3K9me3 at DSBs is required for its activation [50], and is a prerequisite for efficient ATM activation by acetylation. E1B-55K/E4orf6 might interfere with TIP60 binding to H3K9me3 and its activation, possibly contributing to the observed reduction in activated ATM and delayed DDR.

Furthermore, Ad-mediated SPOC1 (Fig. 1 and 2) and TIP60 depletion would promote chromatin relaxation and decreases accessibility of H3K9me3 for TIP60, leading to reduction in ATM activation. So far, several histone H3K9 KMTs were shown to be modulated by SPOC1 (SETDB1, G9A, GLP) [19]. After the onset of viral transcription and efficient E1B-55K/E4orf6 expression, we observe efficient degradation of SPOC1 host factor (Fig. 1 and 2), promoting efficient reduction of H3K9me3 repressive histone marks (Fig. 8). Our findings provide hints that this complex might be altered in stability and activity due to Ad-dependent proteasomal degradation of SPOC1 (Fig. 1, 2 and 8), since these KMTs form a multi-subunit complex that is destabilized by depleting the individual components [51].

In this report, we show that SPOC1 is tightly regulated in the course of productive Ad infection to neutralize host cell defense processes. SPOC1 represents a novel antiviral restriction factor, being associated with Ad major core protein VII and therefore being removed from the viral genome during the very early phase of infection prior to the onset of gene expression during productive virus life cycle (Fig. 10). In other words SPOC1 apparently plays a biphasic role during Ad life cycle by regulating determinants of chromatin compaction and damage response immediately after viral genome entry into the host nucleus, prior to activation of Ad transcription leading to its proteasomal degradation by newly expressed viral proteins.

Besides Ad, different human pathogenic DNA and RNA viruses can impose reduction on SPOC1 protein levels. Our findings provide a model of how viruses might antagonize intrinsic
Figure 7. SPOC1 represses viral transcription. DLD1 or U2OS cells were treated with doxycyclin for 12 hours to induce SPOC1 expression prior to transfection and infection experiments. (A) Transfection with luciferase reporter plasmids under Ad promoter control (E1A, E1B, E2early, MLP). 48 h after transfection, samples were lysed and absolute luciferase activity was measured. All samples were normalized for transfection efficiency by measuring Renilla-luciferase activity. Activity of empty promoter constructs, E1A, E1B, E2early and MLP promoters in non-treated and non-overexpressing cells was normalized to 100%. Mean and STD are from three independent experiments. (B) After infection with H5pg4100 Ad5 wildtype
SPOC1-mediated antiviral responses of their host cells, and create novel awareness for general antiviral restriction factors. These future insights into the immune evasion strategies acquired by viruses and other human pathogens mediated within the host will contribute to identifying new therapeutic strategies and targets to limit or prevent human pathogenic virus-mediated diseases and mortality of patients.

Materials and Methods

Cell culture

HEK293 [52], H1299 [53], SPOC1-inducible U2OS and DLD1 cells [19] were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf serum (FCS), 100 U of penicillin and 100 μg of streptomycin per ml in a 5% CO₂ atmosphere at 37°C. For HepaRG cells, the media was supplemented with 5 μg/ml of bovine insulin and 0.5 μM of hydrocortisone.

Plasmids, mutagenesis and transient transfections

Ad proteins were expressed from their respective complementary DNAs under the control of the CMV immediate-early promoter, derived from the pcDNA3 vector (Invitrogen) to express Ad wild type E1B-55K and E4orf6 [34,35]. cDNAs encoding E1B-55K-products from each Ad type were cloned as described previously [56,57,58]. Transient transfections with luciferase reporter constructs were performed as described previously [2], pRE-Luc and the RGC-firefly luciferase reporter plasmids pGalTK-Luc have been described previously [39], SPOC1 wild type protein was expressed from pcDNA4TO-SPOC1 constructs.

Viruses

H5pg4100 served as the wild type Ad5 parental virus in these studies [60]. The mutant viruses H5pm4149 and H5pm4154 were generated as described recently [61]. Both viruses carry stop codons and do not express the respective viral protein [62]. E4orf6 BC-box mutant virus H5pm4139 was generated, resulting in a drastically reduced ability to associate with the Ad5 E3 ubiquitin ligase complex compared to the E4orf6 protein from wild type virus [61]. Viruses were propagated, titrated and infected as described previously [63]. Virus yield was determined by quantitative E2A-72K immunofluorescence staining and viral DNA replication was monitored by quantitative PCR exactly as described previously [13].

Chromatin Immunoprecipitation Assay (ChIP)

ChIP analysis was performed as described previously [2]. The average Cq-value was determined from triplicate reactions and normalized with standard curves for each primer pair. The identities of the products obtained were confirmed by melting curve analysis.

Luciferase reporter assays

For dual luciferase assays, subconfluent cells were transfected prior to preparation of total cell extracts (48 h) [13]. RGC firefly luciferase and pGL-H2A-promoter activity was assayed with lysed...
The PCR conditions were as follows: 10 min at 95°C, 30 s at 72°C. The average Ct value was determined from triplicate reactions and levels of viral mRNA relative to cellular 18S rRNA were calculated as described recently [13]. The identities of the products obtained were confirmed by melting curve analysis.

### Quantitative real-time (qRT) PCR analysis

Subconfluent cells were infected with wild-type virus and harvested at 24 h p.i.. Total RNA was isolated with Trizol reagent (Invitrogen) as described by the manufacturer. The amount of total RNA was measured and one microgram of RNA was reverse transcribed using the Transcript High Fidelity cDNA Synthesis Sample Kit from Roche including anchored-oligo(dT)18 primer specific to the poly(A) tail of RNA. Quantitative real-time PCR was performed with a first strand method in a Rotor-Gene 6000 (Corbett Life Sciences, Sydney, Australia) in 0.5 ml reaction tubes containing a 1/100 dilution of the cDNA template, 10 pmol/µl of each synthetic oligonucleotide primer, 12.5 µl/sample Power SYBR Green PCR Master Mix (Applied Biosystems). The PCR conditions were as follows: 10 min at 95°C, 55 cycles of 30 s at 95°C, 30 s at 55 to 62°C (depending upon the primer set) and 30 s at 72°C. The average Cq value was determined from triplicate reactions and levels of viral mRNA relative to cellular 18S rRNA were calculated as described recently [13]. The identities of the products obtained were confirmed by melting curve analysis.

### Protein analysis and antibodies (Ab)

For protein analysis cells were resuspended in RIPA buffer as described previously [64]. After 1 h on ice, the lysates were sonicated and the insoluble debris was pelleted at 15,000 x g/4°C. For immunoprecipitation and immunoblotting protein lysates were treated as described recently [2]. Primary Ab specific for Ad proteins used in this study included E1B-55K mab 2A6 [65], E2A-72K mouse mab B6-8 [66], E4orf6 mab RSA3 [67], rabbit polyclonal serum against protein VI [68] and anti-pVII rabbit polyclonal antibody (generously provided by Dan Engel, University of Virginia). To evaluate efficient infection with different RNA and DNA viruses primary antibodies specific for HSV-1 nucleopasid protein (monoclonal mouse mab H1.4; Acris antibodies) crossreacting with HSV-2 nuclear protein, HIV-1 p24 hybridoma 183-H12-5C [69] and HCV NS5A (monoclonal mab 2F6/G11 from immunological and biochemical test systems) were used.

Primary antibodies specific for cellular proteins included SPOC1 rabbit polyclonal CR36 and rat mab [20], rabbit polyclonal ab specific for histone variant H3K9me3 (Upstate), Mre11 rabbit polyclonal antibody pNB 100–142 (Novus Biologicals, Inc.), p53 rabbit ab FL393 (Santa Cruz Biotechnology, Inc.) [70], polyclonal rabbit antibody raised against SAF-A protein [71] and β-actin mouse mab AC-15 (Sigma-Aldrich, Inc.). HA-epitopes were detected with rat monoclonal 3F10 (Roche). Secondary Ab conjugated to horseradish peroxidase (HRP) to detect proteins by immunoblotting were anti-rabbit IgG, anti-rat IgG and antimouse IgG (Jackson/Dianova).

### Indirect immunofluorescence

Cells were prepared and analyzed as described recently [57]. Images were cropped using Adobe Photoshop CS4 and assembled with Adobe Illustrator CS4.

### Supporting Information

**Figure S1** DLD1 and U2OS cells were seeded and treated with doxycyclin to induce SPOC1 expression. The number of living cells was monitored at 1, 3, 5 and 6 days post plating by trypane blue staining to determine the number of cells growing in the absence or presence of doxycyclin.

**Figure S2** H1299 cells were infected with wildtype (H5pg4100) and mutant viruses (H5pm4149, H5pm4154) at moi of 50 FFU per cell. Total-cell extracts were prepared 48 hours post infection. E2A/DBP and E1B-55K were immunoprecipitated using rabbit polyclonal SPOC1 antibody. Proteins were separated on 10% SDS-PAGE and visualized by immunoblotting. Input levels of total-cell lysates and co-precipitated proteins were detected using 

---

*AdS-Mediated Inhibition of SPOC1*

extract in an automated luminometer (Berthold Technologies). All samples were normalized for transfection efficiency by measuring Renilla-luciferase activity. All experiments shown were performed in triplicate and data are presented as mean values.
monoclonal antibody B6-8 (E2A/DBP), 2A6 (E1B-55K), SPOC-1-specific rat monoclonal antibody, and mouse monoclonal antibody AC-15 (β-actin) as a loading control.

**Figure S3** U2OS cells were seeded and treated with doxycyclin to induce SPOC1 expression. After 12 hours U2OS cells were infected with H5pg100 at a MOI of 800 FFU/cell, fractionated at 20 min intervals and subjected to SDS PAGE using SPOC1 specific rat monoclonal antibody, serum against protein VI, polyclonal antibody against the splicing factor SAF-A (nuclear fraction) as indicated to the right.

**Figure S4** H1299 cells were transfected with 0.5 μg of pRenilla-Luc, 0.5 μg pH2A-promoter and 0.5 μg pE2F-1, pDNA4TO-SPOC1 in the combinations indicated (+). Absolute Firefly-luciferase activity is shown with mean and standard deviations from three independent experiments.

---

**Figure 10. Model for factors involved in early stages after Ad5 virus infection.** A schematic representation highlighting the proposed model that pVII recruits SPOC1 to the incoming Ad genome, resulting in pVII-mediated stabilization of SPOC1, followed by its subsequent proteasomal degradation. First, incoming viral DNA is complexed with pV and pVII core/capsid proteins. pVI then mediates interactions with Daxx, ATRX and Nedd4. The pVII/SPOC1 cooperation at viral DNA protects the incoming viral genome from immediate early checkpoint signaling and onset of DNA damage response, resulting in a proviral chromatin microenvironment including KMTs. After activation of viral transcription and E1B-55K/ E4orf6 expression, sequestering of Daxx by E1B-55K and E1B-55K/E4orf6 proteolytic degradation of ATRX and SPOC1 host factors promote efficient reduction of repressive histone marks and resulting in active viral transcription and enhanced Ad5 gene expression.

doi:10.1371/journal.ppat.1003775.g010
Acknowledgments

We thank our colleagues Helga Hoffmann-Sieber, Eva Herker, Kathrin Rosch, and Claus-Henning Nagel from the HPI for providing the different virus-infected probes and reagents. We thank Dan Engel for antibodies against protein VII, Bruce Chesebro and Hardy Chen for HIV-2p42 hybridoma and Gabriele Dobner for technical support.

Author Contributions

Conceived and designed the experiments: SS HK HD. Performed the experiments: SS CB AM TS PG. Analyzed the data: SS TK. Wrote the paper: SS.

References

1. Blanchette P, Branton PE (2009) Manipulation of the ubiquitin-proteasome pathway by small DNA tumor viruses. Virology 384: 317–323.
2. Schreiner S, Martinez R, Groupl P, Rayne F, Vaillant R, et al. (2012) Transcriptional activation of the adenoviral genome is mediated by capsid protein. PLoS Pathog 8: e1002549.
3. Berk AJ (2005) Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 24: 7673–7685.
4. Berschenski J, Groupl P, Dobner T, Wimmer P, Schreiner S (2012) The Adenoviral Oncogene E1A:IS Interacts with a Specific Isoform of the Tumor Suppressor PML To Enhance Viral Transcription. J Virol 87: 965–977.
5. Blackford AN, Grand RJ (2009) Adenovirus E1B 55-kilodalton protein: multiple roles in viral infection and cell transformation. J Virol 83: 4000–4012.
6. Schreiner S, Wimmer P, Dobner T (2012) Adenovirus degradation of cellular proteins. Future Microbiol 7(2): 211–225.
7. Harada EN, Shevchuk A, Pulla DC, Berk AJ (2002) Analysis of the adenovirus E1B-55k-anchored proteome reveals its link to ubiquitination machinery. J Virol 76: 9194–9206.
8. Blanchette P, Cheng CY, Yan Q, Ketter G, Ornelles DA, et al. (2004) Both BC- and CTLS bind to the adenovirus pVIII protein. J Virol 78: 1335–1342.
9. Ragnarsson G, Eiriksdottir G, Johannsdottir JT, Jonasson JG, Egilsson V, et al. (2005) SPOC1 is required for spermatogonial stem cell differentiation and spermatogenesis. J Cell Sci 124: 3137–3148.
10. Mund A, Schubert T, Staeg H, Kinkius S, Reumann K, et al. (2012) Control of Human Adenovirus type 5 (Ad5) gene expression by cellular Daxx/ATRX human adenovirus-infected cells. J Virol 86: 7029–7038.
11. Blackford AN, Patel RN, Forrester NA, Theil K, Groitl P, et al. (2010) Human Adenovirus type 5 E4orf3 protein targets the Mre11 complex to cytoplasmic chromosome condensation. J Cell Sci 122: 2946–2956.
12. Komatsu T, Haruki H, Nagata K (2011) Cellular and viral chromatin proteins cooperate with E4orf6 proteins to destabilize p53. J Virol 74: 193–202.
13. Karen KA, Hearing P (2011) Adenovirus core protein VII protects the viral genome from a DNA damage response at early times after infection. J Virol 85: 4115–4142.
14. Zantema A, Schrier PI, Davis OA, van Laar T, Vaessen RT, et al. (1985) Frequent loss of heterozygosity at 1p36 in ovarian adenocarcinomas but the gene encoding p73 is unlikely to be the target. Oncogene 18: 4640–4657.
15. Evans JD, Hearing P (2003) Distinct Roles of the Adenovirus E4 ORF3 Protein in the Regulation of Adenovirus Gene Expression. J Virol 77: 5283–5290.
16. Evans JD, Hearing P (2005) Relocalization of the Mre11-Rad50-Nbs1 complex by the adenovirus E1B-55k protein directs the nuclear localization of the early region 1B 55-kilodalton protein in primate cells. J Virol 70: 6323–6335.
17. Brown DT, Westphal M, Burlingham BT, Winterhoff U, Doerfler W (1975) Human Adenovirus type 5 E4orf3 protein targets the Mre11-Rad50-Nbs1 DNA repair complex. Nature 253: 342–348.
18. Zanetta A, Schrier PI, Davis OA, van Laar T, Vaessen RT, et al. (1995) Adenovirus p53 and N-methyl-N-nitrosourea-induced p53 and Mdm2. Oncogene 14: 353–362.
19. Zanetta A, Schrier PI, Davis OA, van Laar T, Vaessen RT, et al. (1995) Adenovirus p53 and N-methyl-N-nitrosourea-induced p53 and Mdm2. Oncogene 14: 353–362.
20. Kinkley S, Staege H, Mohrmann G, Rohaly G, Schaub T, et al. (2009) SPOC1: A Novel Protein That Covalently Modified Histone H3 in 36 Chromosome Condensation. J Biol Chem 284: 35467–35474.
21. Imyanitov EN, Birrell GW, Filippovich I, Sorokina N, Arnold J, et al. (1999) Inactivation of the Mre11 Rad50 NBS1 DNA repair complex that degrades p53. Mol Cell Biol 19: 9400–9408.
22. Schreiner S, Wimmer P, Sienna H, Everett RD, Blanchette P, et al. (2010) Proteasome-dependent degradation of Daxx by the viral E1B-55k protein in human adenovirus-infected cells. J Virol 84: 7029–7038.
23. Mohrmann G, Hengstler JG, Hofmann TG, Endele SU, Lee B, et al. (2005) The Adenoviral Oncogene E1A:IS Interacts with a Specific Isoform of the Tumor Suppressor PML To Enhance Viral Transcription. J Virol 87: 965–977.
24. Mohrmann G, Hengstler JG, Hofmann TG, Endele SU, Lee B, et al. (2005) The Adenoviral Oncogene E1A:IS Interacts with a Specific Isoform of the Tumor Suppressor PML To Enhance Viral Transcription. J Virol 87: 965–977.
25. Chi P, Allis CD, Wang GG (2010) Covalent histone modifications—miswritten, misunderstood, and misinterpreted. Nat Rev Mol Cell Biol 11: 63–74.
26. Karen KA, Hearing P (2011) Adenovirus core protein VII protects the viral genome from a DNA damage response at early times after infection. J Virol 85: 4115–4142.
27. Karen KA, Hearing P (2011) Adenovirus core protein VII protects the viral genome from a DNA damage response at early times after infection. J Virol 85: 4115–4142.
28. Karen KA, Hearing P (2011) Adenovirus core protein VII protects the viral genome from a DNA damage response at early times after infection. J Virol 85: 4115–4142.
53. Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D’Amico D, et al. (1992) p53 gene mutations in non-small-lung cell cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7: 171–180.
54. Nevels M, Tauber B, Spruss T, Wolf H, Dohner T (2001) “Hit-and-run” transformation by adenovirus oncoproteins. J Virol 75: 3089–3094.
55. Rubenwolf S, Schutt H, Nevels M, Wolf H, Dohner T (1997) Structural analysis of the adenovirus type 5 E1B 55-kilodalton-E4orf6 protein complex. J Virol 71: 1115–1123.
56. Cheng CY, Gilson T, Dallaire F, Kretzer G, Branton PE, et al. The E4orf6/ E1B55K E3 ubiquitin ligase complexes of human adenoviruses exhibit heterogeneity in composition and substrate specificity. J Virol 85: 765–775.
57. Schreiner S, Wimmer P, Groitl P, Chen SY, Blanchette P, et al. (2011) Adenovirus Type 5 Early Region 1B 55K Oncoprotein-Dependent Degradation of Cellular Factor Daxx Is Required for Efficient Transformation of Primary Rodent Cells. J Virol 85: 8752–8765.
58. Cheng CY, Gilson T, Wimmer P, Schreiner S, Kretzer G, et al. (2013) The role of E1B55K in E4orf6/E1B55K E3 ligase complexes formed by different human adenovirus serotypes. J Virol 87: 6232–45.
59. Nevels M, Rubenwolf S, Spruss T, Wolf H, Dohner T (1997) The adenovirus E4orf6 protein can promote EIA/EIB-induced focus formation by interfering with p53 tumor suppressor function. Proc Natl Acad Sci USA 94: 1206–1211.
60. Groth P, Dohner T (2007) Construction of adenovirus type 5 early region 1 and 4 virus mutants. Methods Mol Med 130: 29–39.
61. Blanchette P, Kindsmüller K, Groth P, Dallaire F, Speiserter T, et al. (2008) Control of mRNA export by adenovirus E4orf6 and E1B55K proteins during productive infection requires E4orf6 ubiquitin ligase activity. J Virol 82: 2642–2651.
62. Kindsmüller K, Groth P, Hartl B, Blanchette P, Hauber J, et al. (2007) Intranuclear targeting and nuclear export of the adenovirus E1B-55K protein are regulated by SUMO1 conjugation. Proc Natl Acad Sci U S A 104: 6684–6689.
63. Kindsmüller K, Schreiner S, Leinenkugel F, Groth P, Kremmer E, et al. (2009) A 49-kilodalton isoform of the adenovirus type 5 early region 1B 55-kilodalton protein is sufficient to support virus replication. J Virol 83: 9045–9056.
64. Wimmer P, Schreiner S, Everett RD, Sirma H, Groth P, et al. (2010) SUMO modification of E1B-55K oncoprotein regulates isoform-specific binding to the tumour suppressor protein PML. Oncogene 29: 5511–5522.
65. Sarnow P, Sullivan CA, Levine AJ (1982) A monoclonal antibody detecting the adenovirus type 5-E1b-58Kd tumor antigen: characterization of the E1b-58Kd tumor antigen in adenovirus-infected and -transformed cells. Virolology 120: 310–317.
66. Reich NG, Sarnow P, Duprey E, Levine AJ (1983) Monoclonal antibodies which recognize native and denatured forms of the adenovirus DNA-binding protein. Virology 128: 480–484.
67. Marton MJ, Bain SB, Ornelles DA, Shenk T (1990) The adenovirus E4 17-kilodalton protein complexes with the cellular transcription factor E2F, altering its DNA-binding properties and stimulating E1A-independent accumulation of E2 mRNA. J Virol 64: 2345–2359.
68. Wodrich H, Hennaf D, Jarzamart B, Segura-Morales C, Seelmeir S, et al. (2010) A capsid-encoded PPxY-motif facilitates adenovirus entry. PLoS Pathog 6: e1000398.
69. Chesbro B, Wehrly K, Nishio J, Perryman S (1992) Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J Virol 66: 6534–6534.
70. Vojtesek B, Bartek J, Midgley CA, Lane DP (1992) An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151: 237–244.
71. Herrmann F, Lee J, Bedford MT, Fackelmayer FO (2005) Dynamics of human protein arginine methyltransferase 1 (PRMT1) in vivo. J Biol Chem 280: 38005–38010.